News from cardio3 biosciences A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( Tokyo:4568,OTC-PINK:DSNKY)

Feb 24, 2014, 08:24 ET

Cardio3 BioSciences Strengthens IP Portfolio with New US Patent

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Jan 09, 2014, 09:00 ET

Cardio3 BioSciences Receives IND Clearance from the FDA for its CHART-2 Phase III Heart Failure Clinical Trial

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Dec 30, 2013, 06:30 ET

Cardio3 BioSciences Announces Participation at the 32nd Annual JP Morgan Healthcare Conference in San Francisco

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Dec 16, 2013, 13:27 ET

Cardio3 BioSciences Raises € 4.0 Million in Non-dilutive Funding from the Walloon Region

The biotechnology company, Cardio3 BioSciences SA ('Cardio3' or 'the Company'), a leader in the discovery and development of regenerative,...

Dec 11, 2013, 12:00 ET

Cardio3 BioSciences C-Cath® Article Published in Circulation Cardiovascular Interventions

  Study Demonstrates Enhanced Endomyocardial Therapeutics Retention through an Optimized Delivery System Cardio3 BioSciences (C3BS) (NYSE...

Dec 03, 2013, 11:35 ET

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 6.8 Million FP7 Research Grant for AMCARE Program

Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Nov 25, 2013, 05:49 ET

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 4.5 Million FP7 Research Grant

Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Nov 21, 2013, 03:00 ET

Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Wallonia

The Belgian biotechnology company Cardio3 BioSciences (C3BS)(NYSE Euronext Brussels and Paris : CARD), leader in the discovery and...

Nov 12, 2013, 12:26 ET

Cardio3 BioSciences Announces Q3 2013 Business Update and Authorization to Enroll Patients in Poland in its Chart-1 Phase III Clinical Trial

Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Oct 23, 2013, 05:56 ET

Cardio3 BioSciences Receives Authorization to Enroll Patients in Italy in its Phase III Clinical Trial CHART-1

- CHART-1 trial represents the world's first Phase III trial in regenerative medicine for a pre-programmed cellular therapy targeting heart...

Oct 17, 2013, 05:47 ET

Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Walloon Brabant

The Belgian biotechnology company Cardio3 BioSciences (C3BS), leader in the discovery and development of regenerative, protective and...

Oct 14, 2013, 01:30 ET

Cardio3 BioSciences to Participate at the KBC Securities Benelux Biotech Healthcare Conference in New York on November 13 & 14

The Belgian biotechnology company Cardio3 BioSciences (C3BS), leader in the discovery and development of regenerative, protective and...

Oct 07, 2013, 02:30 ET

Cardio3 BioSciences Strengthens Management Team by Appointing Dr. Gaëtane Metz as Chief Operating Officer

The Belgian biotechnology company Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative, protective and...

May 08, 2013, 06:19 ET

Cardio3 BioSciences Raises €19 Million Through a Private Placement

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative, protective and...

Apr 11, 2013, 04:00 ET

Results from Cardio3BioSciences C-CURE® Trial Published in the Journal of the American College of Cardiology

  Trial Demonstrates Statistically Significant Improvements in Heart Function and Exercise Tolerance with Cardiopoietic Stem Cell...

Nov 22, 2012, 04:00 ET

Cardio3 BioSciences Receives Authorization to Begin World's First Phase III Clinical Trial in Regenerative Medicine for Heart Failure

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective...

Aug 21, 2012, 03:00 ET

Cardio3 BioSciences Appoints Dr. Alexander Milstein as Vice President of Clinical Development

The Belgian biotechnology company Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies...

May 18, 2012, 04:00 ET

Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at European Society of Cardiology 2012 Heart Failure Congress

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies...

May 09, 2012, 04:00 ET

Cardio3 BioSciences Announces CE Marking for its C-Cath® Injection Catheter

The Belgian biotechnology company, Cardio3--BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies...

Apr 12, 2012, 03:00 ET

Cardio3 BioSciences Granted GMP Certification

The Belgian biotechnology company Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies...